You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • AB0690 Probing the Unique Genetic and Adverse Event Signatures of Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease

Alerts

Article menu
Download PDFPDF
Abstracts Accepted for Publication
Scleroderma, myositis and related syndromes - clinical aspects and treatment
AB0690 Probing the Unique Genetic and Adverse Event Signatures of Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address